Studienliteratur zum Neuroblastom

erstellt am 03.06.2013, Zuletzt geändert:  03.06.2013

Studienliteratur Neuroblastome

 Suche nach Artikeln in den letzten sechs Monaten in PubMed (externes Informationsangebot)
  1. Schumacher-Kuckelkorn R, Atra A, Belli ML, den Engelsman G, Fréneaux P, Gauthier A, Heijlaerts-Klever A, Scuderi F, Senent Peris L, Tewari S, Zapletal O, Ernst A, Berthold F: The reliability of bone marrow cytology as response criterion in metastatic neuroblastoma. Pediatric blood & cancer 2021, 68:e28819 [PMID: 33245195] SCH2021d
  2. Jazmati D, Butzer S, Hero B, Doyen J, Ahmad Khalil D, Steinmeier T, Schulze Schleithoff S, Eggert A, Simon T, Timmermann B: Long-term follow-up of children with neuroblastoma receiving radiotherapy to metastatic lesions within the German Neuroblastoma Trials NB97 and NB 2004. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 2021, 197: 683 [PMID: 33300099] JAZ2021a
  3. Berthold F, Rosswog C, Christiansen H, Frühwald M, Hemstedt N, Klingebiel T, Fröhlich B, Schilling FH, Schmid I, Simon T, Hero B, Fischer M, Ernst A: Clinical and molecular characterization of patients with stage 4(M) neuroblastoma aged less than 18 months without MYCN amplification. Pediatric blood & cancer 2021, 68:e29038 [PMID: 33826231] BER2021a
  4. Schulte JH, Eggert A: ALK Inhibitors in Neuroblastoma: A Sprint from Bench to Bedside. Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Jul 1; 27: 3507 [PMID: 33947691] SCH2021a
  5. Arlt B, Zasada C, Baum K, Wuenschel J, Mastrobuoni G, Lodrini M, Astrahantseff K, Winkler A, Schulte JH, Finkler S, Forbes M, Hundsdoerfer P, Guergen D, Hoffmann J, Wolf J, Eggert A, Kempa S, Deubzer HE: Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma. International journal of cancer 2021, 148: 1219 [PMID: 33284994] ARL2021
  6. Launspach M, Seif M, Thole TM, Jesse P, Schulz J, Schulte JH, Bischoff S, Eggert A, Deubzer HE: Clinical Presentation and Management of a Dinutuximab Beta Extravasation in a Patient with Neuroblastoma. Children (Basel, Switzerland) 2021, 8 [PMID: 33572828] LAU2021
  7. Berthold F, Spix C, Erttmann R, Hero B, Michaelis J, Treuner J, Ernst A, Schilling FH: Neuroblastoma Screening at 1 Year of Age: The Final Results of a Controlled Trial. JNCI cancer spectrum 2021, 5:pkab041 [PMID: 34240006] BER2021
  8. Zirngibl F, Ivasko SM, Grunewald L, Klaus A, Schwiebert S, Ruf P, Lindhofer H, Astrahantseff K, Andersch L, Schulte JH, Lode HN, Eggert A, Anders K, Hundsdoerfer P, Künkele A: GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma. Journal for immunotherapy of cancer 2021, 9 [PMID: 34285106] ZIR2021
  9. Moroz V, Machin D, Hero B, Ladenstein R, Berthold F, Kao P, Obeng Y, Pearson ADJ, Cohn SL, London WB: The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatric blood & cancer 2020, 67:e28359 [PMID: 32472746] MOR2020a
  10. Matthyssens LE, Nuchtern JG, Van De Ven CP, Gabra HOS, Bjornland K, Irtan S, Stenman J, Pio L, Cross KM, Avanzini S, Inserra A, Chacon JG, Dall'igna P, Von Schweinitz D, Holmes K, Fuchs J, Squire R, Valteau-Couanet D, Park JR, Eggert A, Losty PD, La Quaglia MP, Sarnacki S, Surgical and Medical Committees of SIOPEN*, COG** and GPOH***: A Novel Standard for Systematic Reporting of Neuroblastoma Surgery: The International Neuroblastoma Surgical Report Form (INSRF): A Joint Initiative by the Pediatric Oncological Cooperative Groups SIOPEN*, COG**, and GPOH**. Annals of surgery 2020 Jul 7; online ahaed of print [PMID: 32649454] MAT2020
  11. Koche RP, Rodriguez-Fos E, Helmsauer K, Burkert M, MacArthur IC, Maag J, Chamorro R, Munoz-Perez N, Puiggròs M, Dorado Garcia H, Bei Y, Röefzaad C, Bardinet V, Szymansky A, Winkler A, Thole T, Timme N, Kasack K, Fuchs S, Klironomos F, Thiessen N, Blanc E, Schmelz K, Künkele A, Hundsdörfer P, Rosswog C, Theissen J, Beule D, Deubzer H, Sauer S, Toedling J, Fischer M, Hertwig F, Schwarz RF, Eggert A, Torrents D, Schulte JH, Henssen AG: Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma. Nature genetics 2020, 52: 29 [PMID: 31844324] KOC2020
  12. Jazmati D, Butzer S, Hero B, Ahmad Khalil D, Merta J, Bäumer C, Plum G, Fuchs J, Koerber F, Steinmeier T, Peters S, Doyen J, Thole T, Schmidt M, Blase C, Tippelt S, Eggert A, Schwarz R, Simon T, Timmermann B: Proton Beam Therapy for Children With Neuroblastoma: Experiences From the Prospective KiProReg Registry. Frontiers in oncology 2020, 10: 617506 [PMID: 33552991] JAZ2020
  13. Berthold F, Faldum A, Ernst A, Boos J, Dilloo D, Eggert A, Fischer M, Frühwald M, Henze G, Klingebiel T, Kratz C, Kremens B, Krug B, Leuschner I, Schmidt M, Schmidt R, Schumacher-Kuckelkorn R, von Schweinitz D, Schilling FH, Theissen J, Volland R, Hero B, Simon T: Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR. Annals of oncology : official journal of the European Society for Medical Oncology 2020, 31: 422 [PMID: 32067684] BER2020
  14. Matthyssens LE, Nuchtern JG, Van De Ven CP, Gabra HOS, Bjornland K, Irtan S, Stenman J, Pio L, Cross KM, Avanzini S, Inserra A, Chacon JG, Dall'igna P, Von Schweinitz D, Holmes K, Fuchs J, Squire R, Valteau-Couanet D, Park JR, Eggert A, Losty PD, La Quaglia MP, Sarnacki S, Surgical and Medical Committees of SIOPEN*, COG** and GPOH***: A Novel Standard for Systematic Reporting of Neuroblastoma Surgery: The International Neuroblastoma Surgical Report Form (INSRF): A Joint Initiative by the Pediatric Oncological Cooperative Groups SIOPEN*, COG**, and GPOH**. Annals of surgery 2020, [DOI: 10.1097/SLA.0000000000003947] MAT2020
  15. Moreno L, Barone G, DuBois SG, Molenaar J, Fischer M, Schulte J, Eggert A, Schleiermacher G, Speleman F, Chesler L, Geoerger B, Hogarty MD, Irwin MS, Bird N, Blanchard GB, Buckland S, Caron H, Davis S, De Wilde B, Deubzer HE, Dolman E, Eilers M, George RE, George S, Jaroslav Š, Maris JM, Marshall L, Merchant M, Mortimer P, Owens C, Philpott A, Poon E, Shay JW, Tonelli R, Valteau-Couanet D, Vassal G, Park JR, Pearson ADJ: Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. European journal of cancer (Oxford, England : 1990) 2020, 136: 52 [PMID: 32653773] MOR2020
  16. Berthold F: From a single meeting to a scientific community: Quantification of the . Pediatric blood & cancer 2019, 66:e27696 [PMID: 30848089] BER2019
  17. Thole TM, Toedling J, Sprüssel A, Pfeil S, Savelyeva L, Capper D, Messerschmidt C, Beule D, Groeneveld-Krentz S, Eckert C, Gambara G, Henssen AG, Finkler S, Schulte JH, Sieber A, Bluethgen N, Regenbrecht CRA, Kuenkele A, Lodrini M, Eggert A, Deubzer HE: Reflection of neuroblastoma intratumor heterogeneity in the new OHC-NB1 disease model. International journal of cancer 2019 Jul 15; [PMID: 31304977] THO2019
  18. Berthold F, Ernst A, Hero B, Klingebiel T, Kremens B, Schilling FH, Simon T: Correction: Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation. British journal of cancer 2019 Sep 24; [PMID: 31551583] BER2019
  19. Kreitz K, Ernst A, Schmidt R, Simon T, Fischer M, Volland R, Hero B, Berthold F: A new risk score for patients after first recurrence of stage 4 neuroblastoma aged ≥18 months at first diagnosis. Cancer medicine 2019 Oct 20; [PMID: 31631570] KRE2019
  20. Dübbers M, Simon T, Berthold F, Fischer J, Volland R, Hero B, Cernaianu G: Retrospective analysis of relapsed abdominal high-risk neuroblastoma. Journal of pediatric surgery 2018, 53: 558 [PMID: 29021103] DUE2018
  21. Berthold F, Ernst A, Hero B, Klingebiel T, Kremens B, Schilling FH, Simon T: Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation. British journal of cancer 2018, 119: 282 [PMID: 29991700] BER2018
  22. Ackermann S, Cartolano M, Hero B, Welte A, Kahlert Y, Roderwieser A, Bartenhagen C, Walter E, Gecht J, Kerschke L, Volland R, Menon R, Heuckmann JM, Gartlgruber M, Hartlieb S, Henrich KO, Okonechnikov K, Altmüller J, Nürnberg P, Lefever S, de Wilde B, Sand F, Ikram F, Rosswog C, Fischer J, Theissen J, Hertwig F, Singhi AD, Simon T, Vogel W, Perner S, Krug B, Schmidt M, Rahmann S, Achter V, Lang U, Vokuhl C, Ortmann M, Büttner R, Eggert A, Speleman F, O'Sullivan RJ, Thomas RK, Berthold F, Vandesompele J, Schramm A, Westermann F, Schulte JH, Peifer M, Fischer M: A mechanistic classification of clinical phenotypes in neuroblastoma. Science (New York, N.Y.) 2018 Dec 7; 362: 1165 [PMID: 30523111] ACK2018
  23. Berthold F, Spix C, Kaatsch P, Lampert F: Incidence, Survival, and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979-2015. Paediatric drugs 2017, 19: 577 [PMID: 28786082] BER2017a
  24. Ladenstein R, Pötschger U, Pearson ADJ, Brock P, Luksch R, Castel V, Yaniv I, Papadakis V, Laureys G, Malis J, Balwierz W, Ruud E, Kogner P, Schroeder H, de Lacerda AF, Beck-Popovic M, Bician P, Garami M, Trahair T, Canete A, Ambros PF, Holmes K, Gaze M, Schreier G, Garaventa A, Vassal G, Michon J, Valteau-Couanet D, SIOP Europe Neuroblastoma Group (SIOPEN): Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. The Lancet. Oncology 2017, 18: 500 [PMID: 28259608] LAD2017
  25. Moreno L, Caron H, Geoerger B, Eggert A, Schleiermacher G, Brock P, Valteau-Couanet D, Chesler L, Schulte JH, De Preter K, Molenaar J, Schramm A, Eilers M, Van Maerken T, Johnsen JI, Garrett M, George SL, Tweddle DA, Kogner P, Berthold F, Koster J, Barone G, Tucker ER, Marshall L, Herold R, Sterba J, Norga K, Vassal G, Pearson AD: Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. Expert opinion on drug discovery 2017, 12: 801 [PMID: 28604107] MOR2017
  26. Fischer J, Pohl A, Volland R, Hero B, Dübbers M, Cernaianu G, Berthold F, von Schweinitz D, Simon T: Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months. BMC cancer 2017 Aug 4; 17: 520 [PMID: 28778185] FIS2017
  27. Peinemann F, van Dalen EC, Enk H, Berthold F: Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation. The Cochrane database of systematic reviews 2017 Aug 25; 8:CD010685 [PMID: 28840597] PEI2017
  28. Hero B, Clement N, Oera I, Pierron G, Lapouble E, Theissen J, Pasqualini C, Valteau-Couanet D, Plantaz D, Michon J, Delattre O, Tardieu M, Schleiermacher G: Genomic Profiles of Neuroblastoma Associated With Opsoclonus Myoclonus Syndrome. Journal of pediatric hematology/oncology 2018, 40: 93 [PMID: 29135842] HER2017
  29. Berthold F, Hömberg M, Proleskovskaya I, Mazanek P, Belogurova M, Ernst A, Sterba J: Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma. Pediatric hematology and oncology 2017, 34: 308 [PMID: 29148865] BER2017
  30. Simon T, Hero B, Schulte JH, Deubzer H, Hundsdoerfer P, von Schweinitz D, Fuchs J, Schmidt M, Prasad V, Krug B, Timmermann B, Leuschner I, Fischer M, Langer T, Astrahantseff K, Berthold F, Lode H, Eggert A: 2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors. Klinische Padiatrie 2017, 229: 147 [PMID: 28561228] SIM2017
  31. Schmidt M, Hero B, Simon T: I-131-mIBG therapy in neuroblastoma: established role and prospective applications. Clinical and Translational Imaging 2016, Volume 4, Issue 2, 87 [DOI: 10.1007/s40336-016-0173-z] SCH2016e
  32. Morgenstern DA, London WB, Stephens D, Volchenboum SL, Simon T, Nakagawara A, Shimada H, Schleiermacher G, Matthay KK, Cohn SL, Pearson AD, Irwin MS: Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. European journal of cancer (Oxford, England : 1990) 2016, 65: 1 [PMID: 27434878] MOR2016
  33. Meany HJ, London WB, Ambros PF, Matthay KK, Monclair T, Simon T, Garaventa A, Berthold F, Nakagawara A, Cohn SL, Pearson AD, Park JR: Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project. Pediatric blood & cancer 2014, [PMID: 25044743] MEA2014
  34. Simon T, Häberle B, Hero B, von Schweinitz D, Berthold F: Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013, 31: 752 [PMID: 23284039] SIM2013
  35. Simon T, Niemann CA, Hero B, Henze G, Suttorp M, Schilling FH, Berthold F: Short- and long-term outcome of patients with symptoms of spinal cord compression by neuroblastoma. Developmental medicine and child neurology 2012, 54: 347 [PMID: 22329756] SIM2012
  36. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Klingebiel T, Berthold F: Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14. 18 or oral metronomic chemotherapy. BMC Cancer 2011, 18; 11: 21. [PMID: 21244693] SIM2011a
  37. Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B: Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer 2011, 56: 578 [PMID: 21298742] SIM2011
  38. Sudbrock F, Schmidt M, Simon T, Eschner W, Berthold F, Schicha H: Dosimetry for (131)I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma. European journal of nuclear medicine and molecular imaging 2010, [PMID: 20179922] SUD2010
  39. Fischer M, Bauer T, Oberthür A, Hero B, Theissen J, Ehrich M, Spitz R, Eils R, Westermann F, Brors B, König R, Berthold F: Integrated genomic profiling identifies two distinct molecular subtypes with divergent outcome in neuroblastoma with loss of chromosome 11q. Oncogene 2010, 29: 865 [PMID: 19901960] FIS2010
  40. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson AD, INRG Task Force: The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. Journal of clinical oncology 2009, 27: 298 [PMID: 19047290] MON2009
  41. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK, INRG Task Force: The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. Journal of clinical oncology 2009, 27: 289 [PMID: 19047291] COH2009
  42. Oberthuer A, Theissen J, Westermann F, Hero B, Fischer M: Molecular characterization and classification of neuroblastoma. Future oncology (London, England) 2009, 5: 625 [PMID: 19519203] OBE2009
  43. Hoene V, Fischer M, Ivanova A, Wallach T, Berthold F, Dame C: GATA factors in human neuroblastoma: distinctive expression patterns in clinical subtypes. British journal of cancer 2009, 101: 1481 [PMID: 19707195] HOE2009
  44. Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Yalcin B, Dee R, van Noesel MM, Berthold F, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA: Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers. Clinical chemistry 2009, 55: 1316 [PMID: 19460840] STU2009
  45. Benz-Bohm G, Hero B, Gossmann A, Simon T, Körber F, Berthold F: Focal nodular hyperplasia of the liver in longterm survivors of neuroblastoma How much diagnostic imaging is necessary? European journal of radiology 2009, [PMID: 19369017] BEN2009
  46. Voth H, Oberthuer A, Simon T, Kahlert Y, Berthold F, Fischer M: Co-regulated expression of HAND2 and DEIN by a bidirectional promoter with asymmetrical activity in neuroblastoma. BMC molecular biology 2009, 10: 28 [PMID: 19348682] VOT2009
  47. Theissen J, Boensch M, Spitz R, Betts D, Stegmaier S, Christiansen H, Niggli F, Schilling F, Schwab M, Simon T, Westermann F, Berthold F, Hero B: Heterogeneity of the MYCN oncogene in neuroblastoma. Clinical cancer research 2009, 15: 2085 [PMID: 19276282] THE2009
  48. Schmidt M, Simon T, Hero B, Schicha H, Berthold F: The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. European journal of cancer (Oxford, England : 1990) 2008, 44: 1552 [PMID: 18424129] SCH2008c
  49. Westermann F, Muth D, Benner A, Bauer T, Henrich KO, Oberthuer A, Brors B, Beissbarth T, Vandesompele J, Pattyn F, Hero B, König R, Fischer M, Schwab M: Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome biology 2008, 9:R150 [PMID: 18851746] WES2008
  50. Bénard J, Raguénez G, Kauffmann A, Valent A, Ripoche H, Joulin V, Job B, Danglot G, Cantais S, Robert T, Terrier-Lacombe MJ, Chassevent A, Koscielny S, Fischer M, Berthold F, Lipinski M, Tursz T, Dessen P, Lazar V, Valteau-Couanet D: MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S. Molecular oncology 2008, 2: 261 [PMID: 19383347] BEN2008
  51. Oberthuer A, Kaderali L, Kahlert Y, Hero B, Westermann F, Berthold F, Brors B, Eils R, Fischer M: Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR. Clinical cancer research : an official journal of the American Association for Cancer Research 2008, 14: 6590 [PMID: 18927300] OBE2008
  52. Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Kleijn I, Dee R, Hooft L, van Noesel MM, Bierings M, Berthold F, Versteeg R, Caron HN, van der Schoot CE, Tytgat GA: PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. Journal of clinical oncology 2008, 26: 5443 [PMID: 18838715] STU2008
  53. Fischer M, Spitz R, Oberthür A, Westermann F, Berthold F: Risk estimation of neuroblastoma patients using molecular markers. Klinische Padiatrie 2008, 220: 137 [PMID: 18478485] FIS2008
  54. Hero B, Simon T, Spitz R, Ernestus K, Gnekow AK, Scheel-Walter HG, Schwabe D, Schilling FH, Benz-Bohm G, Berthold F: Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. Journal of clinical oncology 2008, 26: 1504 [PMID: 18349403] HER2008
  55. Voth H, Oberthuer A, Simon T, Kahlert Y, Berthold F, Fischer M: Identification of DEIN, a novel gene with high expression levels in stage IVS neuroblastoma. Molecular cancer research : MCR 2007, 5: 1276 [PMID: 18171985] VOT2007
  56. Simon T, Längler A, Berthold F, Klingebiel T, Hero B: Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial. Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology 2007, 29: 101 [PMID: 17279006] SIM2007
  57. Schmidt M, Simon T, Hero B, Eschner W, Dietlein M, Sudbrock F, Bongartz R, Berthold F, Schicha H: Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004. Nuklearmedizin. Nuclear medicine 2006, 45: 145-51; quiz N39 [PMID: 16964339] SCH2006b
  58. Oberthuer A, Warnat P, Kahlert Y, Westermann F, Spitz R, Brors B, Hero B, Eils R, Schwab M, Berthold F, Fischer M: Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease. Cancer letters 2007, 250: 250 [PMID: 17126996] OBE2006a
  59. Spitz R, Oberthuer A, Zapatka M, Brors B, Hero B, Ernestus K, Oestreich J, Fischer M, Simon T, Berthold F: Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes, chromosomes & cancer 2006, 45: 1130 [PMID: 16958102] SPI2006a
  60. Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, Ernestus K, König R, Haas S, Eils R, Schwab M, Brors B, Westermann F, Fischer M: Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006, 24: 5070 [PMID: 17075126] OBE2006
  61. Fischer M, Oberthuer A, Brors B, Kahlert Y, Skowron M, Voth H, Warnat P, Ernestus K, Hero B, Berthold F: Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome. Clinical cancer research : an official journal of the American Association for Cancer Research 2006, 12: 5118 [PMID: 16951229] FIS2006
  62. Simon T, Hero B, Bongartz R, Schmidt M, Müller RP, Berthold F: Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease. Strahlentherapie und Onkologie 2006, 182: 389 [PMID: 16826357] SIM2006
  63. Spitz R, Hero B, Simon T, Berthold F: Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clinical cancer research 2006, 12(11 Pt 1): 3368 [PMID: 16740759] SPI2006
  64. Schumacher-Kuckelkorn R, Hero B, Ernestus K, Berthold F: Lacking immunocytological GD2 expression in neuroblastoma: report of 3 cases. Pediatric blood & cancer 2005, 45: 195 [PMID: 15800908] SCH2005a
  65. Hero B, Berthold F: Neuroblastoma. In: D. Reinhard (Hrsg.), Leitlinien Kinderheilkunde und Jugendmedizin Urban & Fischer, 2005, L5 1 [ISBN: 3-437-21867-0] HER2005
  66. Fischer M, Skowron M, Berthold F: Reliable transcript quantification by real-time reverse transcriptase-polymerase chain reaction in primary neuroblastoma using normalization to averaged expression levels of the control genes HPRT1 and SDHA. The Journal of molecular diagnostics 2005, 7: 89 [PMID: 15681479] FIS2005
  67. Wolfl M, Jungbluth AA, Garrido F, Cabrera T, Meyen-Southard S, Spitz R, Ernestus K, Berthold F: Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer immunology, immunotherapy : CII 2005, 54: 400 [PMID: 15449039] WOE2005
  68. Eich HT, Muller RP, Micke O, Kocher M, Berthold F, Hero B: Esthesioneuroblastoma in childhood and adolescence. Better prognosis with multimodal treatment? Strahlentherapie und Onkologie 2005, 181: 378 [PMID: 15925980] EIC2005
  69. Boensch M, Oberthuer A, Fischer M, Skowron M, Oestreich J, Berthold F, Spitz R: Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q. Diagnostic molecular pathology 2005, 14: 177 [PMID: 16106200] BOE2005
  70. Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, Klingebiel T, Kremens B, Schilling FH, Schrappe M, Simon T, Hero B: Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. The lancet oncology 2005, 6: 649 [PMID: 16129365] BER2005
  71. Simon A, Beutel K, Marklein G, Fleischhack G: Bacterial infections in pediatric cancer patients. Klin Pädiatr 2005, 217 Suppl 1:S17 [PMID: 16288351] SIM2005
  72. Claviez A, Lakomek M, Ritter J, Suttorp M, Kremens B, Dickerhoff R, Harms D, Berthold F, Hero B: Low occurrence of familial neuroblastomas and ganglioneuromas in five consecutive GPOH neuroblastoma treatment studies. European journal of cancer (Oxford, England : 1990) 2004, 40: 2760 [PMID: 15648116] CLA2004c
  73. Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Niethammer D, Berthold F: Consolidation treatment with chimeric anti-GD2-antibody ch14. 18 in children older than 1 year with metastatic neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004, 22: 3549 [PMID: 15337804] SIM2004a
  74. Wei JS, Greer BT, Westermann F, Steinberg SM, Son CG, Chen QR, Whiteford CC, Bilke S, Krasnoselsky AL, Cenacchi N, Catchpoole D, Berthold F, Schwab M, Khan J: Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer research 2004, 64: 6883 [PMID: 15466177] WEI2004a
  75. Jensen M, Tawadros S, Sedlacek HH, Schultze JL, Berthold F: NK cell depletion diminish tumour-specific B cell responses. Immunology letters 2004, 93(2-3): 205 [PMID: 15158618] JEN2004
  76. Spitz R, Hero B, Skowron M, Ernestus K, Berthold F: MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification. European journal of cancer (Oxford, England : 1990) 2004, 40: 2753 [PMID: 15571958] SPI2004
  77. Schilling FH, Spix C, Berthold F, Erttmann R, Sander J, Treuner J, Michaelis J: Children may not benefit from neuroblastoma screening at 1 year of age. Updated results of the population based controlled trial in Germany. Cancer letters 2003, 197(1-2): 19 [PMID: 12880955] SCH2003j
  78. Spitz R, Hero B, Ernestus K, Berthold F: Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2003, 9: 4835 [PMID: 14581355] SPI2003d
  79. Berthold F, Hero B, Kremens B, Handgretinger R, Henze G, Schilling FH, Schrappe M, Simon T, Spix C: Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer letters 2003, 197(1-2): 11 [PMID: 12880954] BER2003a
  80. Simon T, Hero B, Hunneman DH, Berthold F: Tumour markers are poor predictors for relapse or progression in neuroblastoma. European journal of cancer (Oxford, England : 1990) 2003, 39: 1899 [PMID: 12932669] SIM2003a
  81. Krams M, Heidebrecht HJ, Hero B, Berthold F, Harms D, Parwaresch R, Rudolph P: Repp86 expression and outcome in patients with neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003, 21: 1810 [PMID: 12721258] KRA2003a
  82. Jensen M, Ernestus K, Kemshead J, Klehr M, Von Bergwelt-Baildon MS, Schinkothe T, Schultze JL, Berthold F: The bi-specific CD3 x NCAM antibody: a model to preactivate T cells prior to tumour cell lysis. Clinical and experimental immunology 2003, 134: 253 [PMID: 14616785] JEN2003